What is the stock price of CYTK today?
Cytokinetics, Incorporated (NASDAQ: CYTK) trades at $76.45 per share, supported by a robust market capitalization exceeding $10.3 billion. As a late-stage biopharmaceutical enterprise specializing in novel muscle biology therapeutics for cardiovascular and neuromuscular diseases, its valuation is heavily powered by clinical trial advancements, regulatory milestones, and strong institutional investor confidence.
Related FAQs
No, Cytokinetics (CYTK) does not pay dividends. As a growth-focused biotechnology company, it prioritizes the reinvestment of all available capital into its research, development, and commercialization efforts.
Aficamten (marketed under brand names such as Myqorzo) has been authorized as a once-daily oral cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy.
The professional analyst consensus for Cytokinetics is a "Strong Buy," with virtually all covering analysts recommending that investors buy or hold the stock rather than sell.
As of July 2026, the overwhelming consensus rating for Cytokinetics is a "Buy," with a significant percentage of analysts classifying it as a "Strong Buy".
Market analyst consensus ratings for Tetra Tech, trading under the ticker symbol TTEK, generally feature favorable buy or hold recommendations as equity researchers evaluate robust demand for environmental engineering, water management, and sustai...
Yes, Dominion Energy (D) pays a quarterly dividend to its shareholders.
Cytokinetics is a late-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing muscle biology-directed medicines for treating serious cardiovascular and neuromuscular diseases.
Construction firms operating under names matching D Construction represent regional engineering, heavy civil contracting, and commercial building enterprises holding multi-million-dollar asset valuations.
Wall Street equity research analysts covering Cytokinetics, Incorporated (CYTK) establish a consensus 12-month average price target of approximately $99.37 to $105.00 per share.
Dacotah Bank is an established regional financial institution headquartered in Aberdeen, South Dakota, maintaining total consolidated assets exceeding $3.1 billion.
Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on pioneering scientific innovations in muscle biology and developing potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.
Securities or corporate entities trading under ticker abbreviations similar to CELC are evaluated by financial professionals on a case-by-case basis depending on their specific industry sector, such as biotechnology or specialized technology.
Cytokinetics has developed key cardiovascular drug candidates, notably aficamten (marketed under the brand name MYQORZO), which is a cardiac myosin inhibitor designed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyop...
Cytokinetics is widely considered a promising player in the biotechnology sector, garnering strong positive sentiment from market analysts who view its future prospects favorably.
Analyst sentiment for Cytokinetics (CYTK) is overwhelmingly positive, with a consensus rating of "Buy" or "Strong Buy" among market professionals as of mid-2026.